Biodel Announces Schedule for Data Presentations at American Diabetes Association Annual Meeting

Jun 14, 2010, 07:00 ET from Biodel Inc.

DANBURY, Conn., June 14 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the following oral and poster presentations describing results from studies of the company's product candidates will be presented during the 70th Scientific Sessions of the American Diabetes Association this month in Orlando, Florida:

Oral Presentation:

#36-OR, Oral Session on Insulin Therapy, June 25, 5pm, "An Open-Label Multicenter Trial of VIAject® vs. Regular Human Insulin in Patients With Type 2 Diabetes: Final Analyses"; presented by Helena Rodbard, MD, Endocrine and Metabolic Consultants, LLC

Poster Presentations:

#1411-P, Category 15-C, June 26, 11:30am, "Pharmacokinetics and Pharmacodynamics of a New Rapid Acting Insulin Formulation 'Vialog' in the Diabetic Swine Model"; presented by Roderike Pohl, PhD, Biodel Inc.

#642-P, Category 01-D, June 28, 12pm, "An Open-Label, Multicenter Trial of VIAject® vs. Regular Human Insulin in Patients with Type 1 Diabetes: Impact of Regional Differences on Efficacy Analyses"; presented by Priscilla Hollander, MD, Baylor University Medical Center

#622-P, Category 01-D, June 28, 12pm, "A Novel pH-Neutral Formulation of the Monomeric Insulin VIAject® Has a Faster Onset of Action Than Insulin Lispro"; presented by Tim Heise, MD, Profil Institut fur Stoffwechselforschung

The abstracts can also be accessed by registered meeting attendees through the association's web site, www.diabetes.org.  

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes.  Biodel's product candidates are developed using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs.  Biodel's new drug application for its most advanced product candidate, VIAject(R), has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010.  Earlier-stage product candidates include VIAtab(TM), a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at www.biodel.com.

BIOD-G

Contact:

The Trout Group LLC

Seth D. Lewis, +1-646-378-2952

SOURCE Biodel Inc.



RELATED LINKS

http://www.biodel.com